Biomarker and Diagnostics Strategy

This is where precision medicine starts – whether you’re trying to find the right tools to uncover new biomarkers, identify CDx partners, launch an IVD, or understand how your assay will fit into the clinical journey, DeciBio has you covered. Nobody knows biomarkers and CDx better than DeciBio.

Our Experts

Andrew Aijian

Stephane Budel

David Cavanaugh

David Cavanaugh

Schedule a Call

Related Client Results

All Client Results

Clinical Diagnostics

Longitudinal Monitoring of Cancer Early Detection Market

A top-10 diagnostics player wanted to monitor market development activities and competitive intelligence in the early cancer detection space

Competitive Analysis

Clinical Diagnostics

RNA-based Oncology Biomarker Market Landscape

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

Voice-of-Customer Research

Competitive Analysis

Biomarker and Diagnostics Strategy

Product Specification Mapping

Pharma & Biotech

Synthetic mRNA Production Landscape Assessment

A UK-based life science services provider was interested in learning more about the value and market landscape for synthetic mRNA production to inform a potential acquisition strategy

Voice-of-Customer Research

Competitive Analysis

Market Landscaping and Sizing

Financial Services

PE-Backed Life Sciences Tools Platform Development

A leading private equity firm and management team sought out DeciBio as a strategic partner to advise on the life sciences market and perform due-diligences in support of the development of a novel life sciences tools platform

Voice-of-Customer Research

Customer Segmentation

Pricing Strategy

Due Diligence

Competitive Analysis

RWD Biobank Offering Go-to-Market Strategy

The ventures arm of a top-20 U.S. health system sought support developing a go-to-market strategy for RWD-augmented biobank offerings

Voice-of-Customer Research

Go-to-Market Strategy

Pricing Strategy

Competitive Analysis

Pharma & Biotech

Early-Stage Cancer Biomarker Testing and Treatment Landscape Assessment

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

Competitive Analysis

Voice-of-Customer Research

Precision Medicine is evolving at a rapid pace

Discover how we can help